A new update to the American Diabetes Association s Standards of Care advises use of the fibrosis-4 (FIB-4) index for screening and use of GLP-1 agonists or pioglitazone for treatment.
/PRNewswire/ On April 27, 2022, GyroStim became the first FDA-cleared device for treating balance disorders to receive FDA designation as a Breakthrough.